Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Post-Transplant Events

Clonal gammopathies following alemtuzumab-based reduced intensity conditioning haematopoietic stem cell transplantation: association with chronic graft-versus-host disease and improved overall survival

Bone Marrow Transplantation volume 40, pages 747–752 (2007)Cite this article

Abstract

The presence of clonal gammopathies (CG) has been reported following both conventional myeloablative and autologous haematopoietic stem cell transplantation (HSCT). We monitored the occurrence of CG in a cohort of patients with myeloid malignancies receiving FBC (fludarabine-busulphan-alemtuzumab)-based reduced intensity conditioned (RIC) HSCT, and assessed its correlation with infections, graft-versus-host disease (GvHD) and survival. Serial serum protein electrophoresis was analysed in a total of 138 patients and CG were detected in 49 patients (36%). The predominant Ig isotype was IgG (82%). There was no difference in the incidence of viral infections between patient groups. However, patients with gammopathies were more likely to have had prior chronic GvHD (OR 2.7, 95% CI 1.3–5.5, P<0.001). On multivariate analysis, the only factors that were found to influence overall survival (OS) were presence of gammopathies, which was associated with an improved OS (OR 0.35 95% CI 0.14–0.86, P=0.02) as well as disease stage, patients with advanced disease having a higher risk of death (OR 2.20 95% CI 1.18–4.11, P=0.02). Disease stage was the only variable that influenced relapse incidence on multivariate analysis (OR 4.22 95% CI 1.82–9.78, P<0.01). Clonal gammopathies are a frequent but benign occurrence following alemtuzumab-based RIC HSCT, and their appearance may define a group of patients with a favourable overall outcome.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

Similar content being viewed by others

References

  1. Slavin S, Nagler A, Naparstek E, Kapelushnik Y, Aker M, Cividalli G et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 1998; 91: 756–763.

    CAS  PubMed  Google Scholar 

  2. Rouquette-Gally AM, Boyeldieu D, Prost AC, Gluckman E . Autoimmunity after allogeneic bone marrow transplantation. A study of 53 long-term-surviving patients. Transplantation 1988; 46: 238–240.

    Article  CAS  PubMed  Google Scholar 

  3. Sherer Y, Shoenfeld Y . Autoimmune diseases and autoimmunity post-bone marrow transplantation. Bone Marrow Transplant 1998; 22: 873–881.

    Article  CAS  PubMed  Google Scholar 

  4. Shenoy S, Mohanakumar T, Todd G, Westhoff W, Dunnigan K, Adkins D et al. Immune reconstitution following allogeneic peripheral blood stem cell transplants. Bone Marrow Transplant 1999; 23: 335–346.

    Article  CAS  PubMed  Google Scholar 

  5. Noel DR, Witherspoon RP, Storb R, Atkinson K, Doney K, Mickelson E et al. Does graft-versus-host disease influence the tempo of immunologic recovery after allogeneic human marrow transplantation? An observation on 56 long-term survivors. Blood 1978; 51: 1087–1105.

    CAS  PubMed  Google Scholar 

  6. D’Sa S, Peggs K, Pizzey A, Verfuerth S, Thuraisundaram D, Watts M et al. T- and B-cell immune reconstitution and clinical outcome in patients with multiple myeloma receiving T-cell-depleted, reduced-intensity allogeneic stem cell transplantation with an alemtuzumab-containing conditioning regimen followed by escalated donor lymphocyte infusions. Br J Haematol 2003; 123: 309–322.

    Article  PubMed  Google Scholar 

  7. Loh Y, Oyama Y, Statkute L, Quigley K, Yaung K, Gonda E et al. Development of a secondary autoimmune disorder after hematopoietic stem cell transplantation for autoimmune diseases: role of conditioning regimen used? Blood 2007; 109: 2643–2648.

    Article  CAS  PubMed  Google Scholar 

  8. Ho AY, Pagliuca A, Kenyon M, Parker JE, Mijovic A, Devereux S et al. Reduced-intensity allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome and acute myeloid leukemia with multilineage dysplasia using fludarabine, busulphan, and alemtuzumab (FBC) conditioning. Blood 2004; 104: 1616–1623.

    Article  CAS  PubMed  Google Scholar 

  9. Mitus AJ, Stein R, Rappeport JM, Antin JH, Weinstein HJ, Alper CA et al. Monoclonal and oligoclonal gammopathy after bone marrow transplantation. Blood 1989; 74: 2764–2768.

    CAS  PubMed  Google Scholar 

  10. Hammarstrom L, Smith CI . Frequent occurrence of monoclonal gammopathies with an imbalanced light-chain ratio following bone marrow transplantation. Transplantation 1987; 43: 447–449.

    Article  CAS  PubMed  Google Scholar 

  11. Nagashima T, Muroi K, Kawano-Yamamoto C, Komatsu N, Ozawa K . Paraproteinemia after hematopoietic stem cell transplantation. Leuk Lymphoma 2004; 45: 135–137.

    Article  PubMed  Google Scholar 

  12. Morecki S, Gelfand Y, Nagler A, Or R, Naparstek E, Varadi G et al. Immune reconstitution following allogeneic stem cell transplantation in recipients conditioned by low intensity vs myeloablative regimen. Bone Marrow Transplant 2001; 28: 243–249.

    Article  CAS  PubMed  Google Scholar 

  13. Buggins AG, Mufti GJ, Salisbury J, Codd J, Westwood N, Arno M et al. Peripheral blood but not tissue dendritic cells express CD52 and are depleted by treatment with alemtuzumab. Blood 2002; 100: 1715–1720.

    CAS  PubMed  Google Scholar 

  14. Myint H, Copplestone JA, Orchard J, Craig V, Curtis D, Prentice AG et al. Fludarabine-related autoimmune haemolytic anaemia in patients with chronic lymphocytic leukaemia. Br J Haematol 1995; 91: 341–344.

    Article  CAS  PubMed  Google Scholar 

  15. Hebart H, Einsele H, Klein R, Fischer I, Buhler S, Dietz K et al. CMV infection after allogeneic bone marrow transplantation is associated with the occurrence of various autoantibodies and monoclonal gammopathies. Br J Haematol 1996; 95: 138–144.

    Article  CAS  PubMed  Google Scholar 

  16. Soderberg C, Larsson S, Rozell BL, Sumitran-Karuppan S, Ljungman P, Moller E . Cytomegalovirus-induced CD13-specific autoimmunity – a possible cause of chronic graft-vs-host disease. Transplantation 1996; 61: 600–609.

    Article  CAS  PubMed  Google Scholar 

  17. Moller E, Bohme J, Valugerdi MA, Ridderstad A, Olerup O . Speculations on mechanisms of HLA associations with autoimmune diseases and the specificity of ‘autoreactive’ T lymphocytes. Immunol Rev 1990; 118: 5–19.

    Article  CAS  PubMed  Google Scholar 

  18. Chakrabarti S, Mackinnon S, Chopra R, Kottaridis PD, Osman H, Waldmann H et al. High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation: potential role of Campath-1H in delaying immune reconstitution. Blood 2002; 99: 4357–4363.

    Article  CAS  PubMed  Google Scholar 

  19. Chakrabarti S, Avivi I, Mackinnon S, Ward K, Kottaridis PD, Osman H et al. Respiratory virus infections in transplant recipients after reduced-intensity conditioning with Campath-1H: high incidence but low mortality. Br J Haematol 2002; 119: 1125–1132.

    Article  PubMed  Google Scholar 

  20. Hanto DW, Frizzera G, Gajl-Peczalska KJ, Simmons RL . Epstein-Barr virus, immunodeficiency, and B cell lymphoproliferation. Transplantation 1985; 39: 461–472.

    Article  CAS  PubMed  Google Scholar 

  21. Miklos DB, Kim HT, Miller KH, Guo L, Zorn E, Lee SJ et al. Antibody responses to H-Y minor histocompatibility antigens correlate with chronic graft-versus-host disease and disease remission. Blood 2005; 105: 2973–2978.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Haematological Medicine, Kings College London and Kings College Hospital, London, UK

    Z Y Lim, W Ingram, M Akthari, D Milojkovic, A Y L Ho, S Devereux, A Pagliuca, R F Duarte & G J Mufti

  2. Department of Medical Statistics and BioInformatics, Leiden University Medical Center, Leiden, The Netherlands

    R Brand

Authors
  1. Z Y Lim
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. W Ingram
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. R Brand
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M Akthari
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. D Milojkovic
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. A Y L Ho
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. S Devereux
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. A Pagliuca
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. R F Duarte
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. G J Mufti
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to G J Mufti.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lim, Z., Ingram, W., Brand, R. et al. Clonal gammopathies following alemtuzumab-based reduced intensity conditioning haematopoietic stem cell transplantation: association with chronic graft-versus-host disease and improved overall survival. Bone Marrow Transplant 40, 747–752 (2007). https://doi.org/10.1038/sj.bmt.1705805

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1705805

Keywords

This article is cited by

Search

Advanced search

Quick links